News Lilly takes POINT in radiopharma push Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.
News Lantheus on POINT in radio-oncology with $2bn licensing deal Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.
News Roche adds another obesity drug with $1.16bn Rona deal Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ALK7.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
